Jeffrey Weber, MD, PhD, was recruited to NYULMC in 2015 from the H. Lee Moffitt Cancer Center, where he was Director of the Donald A. Adam Comprehensive Melanoma Research Center and Director and PI of the Moffitt Skin Cancer SPORE. Previously the Chief of Medical Oncology and Associate Director for Clinical Research at the USC/Norris Comprehensive Cancer Center, his expertise in human immunology and immune therapies spans bench and bedside, focusing on monitoring and characterizing T cell responses in patients, developing immunotherapeutic antibodies and identifying biomarkers of efficacy and immune-related toxicity. Dr. Weber led initial tests of ipilimumab and nivolumab in patients with metastatic melanoma and is a thought leader in the clinical management of novel immune-related adverse events (irAEs). His laboratory has identified pre-treatment biomarkers that predict ipilimumab response and has also developed in vitro and in vivo models demonstrating that PD-1 antibodies can alter T regulatory cell suppression and MDSC inhibition, leading to clinical trials of nivolumab in ipilimumab-refractory patients. Dr. Weber has initiated more than 110 immunotherapy trials in advanced melanoma, has held more than 12 investigator INDs and is still dedicated to the clinical care of melanoma patients. He has served on the NCI’s Clinical Oncology Study Section, was chair of the VA’s Clinical Oncology Study Section, as a scientific advisor to multiple cancer-related biotechnology companies and as a board member of the Melanoma Research Foundation and the Melanoma Research Alliance.